{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T15:14:26Z","timestamp":1747149266493,"version":"3.40.5"},"reference-count":18,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["IJU Case Reports"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The efficacy of nivolumab for non\u2010clear cell renal cell carcinoma is still unclear. We present a rare case of metastatic papillary renal cell carcinoma remarkably responded to nivolumab but developed myeloradiculoneuropathy as immune\u2010related adverse event.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>The patient had previously undergone radical nephrectomy for right renal mass and was diagnosed as papillary renal cell carcinoma type 2, pT3bN0M0. Three years after the first surgery, he received 3\u00a0mg\/kg of nivolumab as a second\u2010line drug for mediastinum lymph nodes and lung metastases. With three cycles of nivolumab, the patient felt progressive weakness of the legs and received two cycles of steroid\u2010pulse therapy based on the diagnosis of myeloradiculoneuropathy. Although nivolumab therapy has been discontinued, the metastases show radiographic complete response at 2\u00a0years after the last nivolumab administration without any additional therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Nivolumab may be a promising treatment option for non\u2010clear cell renal cell carcinoma such as papillary renal cell carcinoma.<\/jats:p><\/jats:sec>","DOI":"10.1002\/iju5.12262","type":"journal-article","created":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T05:56:40Z","timestamp":1613627800000},"page":"139-142","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Only three cycles of nivolumab showed remarkable durable response and reversible myeloradiculoneuropathy in a patient with metastatic papillary renal cell carcinoma type 2"],"prefix":"10.1002","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7839-5861","authenticated-orcid":false,"given":"Kazunori","family":"Iwasaki","sequence":"first","affiliation":[{"name":"Department of Urology Oita University Faculty of Medicine Yufu Oita Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshitaka","family":"Shin","sequence":"additional","affiliation":[{"name":"Department of Urology Oita University Faculty of Medicine Yufu Oita Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Urology Oita University Faculty of Medicine Yufu Oita Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadamasa","family":"Shibuya","sequence":"additional","affiliation":[{"name":"Department of Urology Oita University Faculty of Medicine Yufu Oita Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Hirai","sequence":"additional","affiliation":[{"name":"Department of Urology Oita University Faculty of Medicine Yufu Oita Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadasuke","family":"Ando","sequence":"additional","affiliation":[{"name":"Department of Urology Oita University Faculty of Medicine Yufu Oita Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromitsu","family":"Mimata","sequence":"additional","affiliation":[{"name":"Department of Urology Oita University Faculty of Medicine Yufu Oita Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,2,17]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"Japanese Urological Association.Clinical practice guidelines for renal cell carcinoma.2017. [Cited Jan 2021.] Available from URL:https:\/\/www.urol.or.jp\/lib\/files\/other\/guideline\/29_renal_cancer_2017.pdf(In Japanese)."},{"key":"e_1_2_8_3_1","unstructured":"LjungbergB BexA GilesRHet al.EAU guidelines on renal cell carcinoma.2019. [Cited Apr 2020.] Available from URL:https:\/\/uroweb.org\/guideline\/renal\u2010cell\u2010carcinoma\/."},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2017.0100"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.0054"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510665"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71222-7"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0319-9"},{"key":"e_1_2_8_9_1","first-page":"1","article-title":"Nivolumab for the treatment of patients with metastatic non\u2010clear cell renal cell carcinoma (nccRCC): a single\u2010institutional experience and literature meta\u2010analysis","volume":"24","author":"Chahoud J","year":"2019","journal-title":"Oncologist"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.07.008"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-017-0469-5"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13691-019-00379-1"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2016.00250"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyaa229"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8111777"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2019.03.003"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-6150-y"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.11.019"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyy106"}],"container-title":["IJU Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/iju5.12262","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/iju5.12262","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/iju5.12262","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T22:46:23Z","timestamp":1693608383000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/iju5.12262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,17]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10.1002\/iju5.12262"],"URL":"https:\/\/doi.org\/10.1002\/iju5.12262","archive":["Portico"],"relation":{},"ISSN":["2577-171X","2577-171X"],"issn-type":[{"type":"print","value":"2577-171X"},{"type":"electronic","value":"2577-171X"}],"subject":[],"published":{"date-parts":[[2021,2,17]]},"assertion":[{"value":"2020-11-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}